Nexavar as adjuvant misses in Phase III HCC trial

Bayer AG (Xetra:BAYN) and partner Onyx Pharmaceuticals Inc. said twice-daily oral Nexavar sorafenib as adjuvant treatment missed the primary endpoint of improving recurrence-free survival vs. placebo in the Phase III STORM trial to prevent recurrence of hepatocellular carcinoma (HCC). The double-blind, international trial enrolled about 1,100 HCC patients who had no detectable disease after surgical resection or local tumor ablation.

Nexavar is approved in more than 100 countries to treat unresectable HCC and advanced renal cell carcinoma (RCC). In the U.S., the inhibitor of CRAF (RAF1) and multiple receptor tyrosine kinases is also approved for locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment. ...